Religare Enterprises Q4 FY26 & FY2026: The Burman Era Begins as Religare Pivots Toward a Demerger Battleground

Religare Enterprises Limited (REL) is no longer the “sick child” of the Indian financial services sector. After years of navigating the wreckage left by its former promoters and a grueling debt resolution process, the company has officially entered its “Phase 2.0.” The narrative has shifted from survival to structural engineering. With the Burman Group (Dabur promoters) now firmly in the driver’s seat with a 30.27% stake, the organization is undergoing a radical DNA transplant.

The headline for FY26 isn’t just the ₹8,494 crore consolidated revenue; it’s the strategic decision to split the empire. The Board has greenlit a demerger that will carve out the lending and broking businesses into a separately listed entity, Religare Finvest (RFL), leaving the crown jewel—Care Health Insurance—within the original REL shell. While the market digests this 1:1 share swap, the financial statements reveal a complex transition where “timing differences” in insurance accounting are clashing with the aggressive revival of the lending books.

1. At a Glance

The financial year 2026 has been a year of “The Great Clean-up.” Religare Enterprises is currently a house undergoing a massive structural renovation while the family is still living in it. If you look at the surface-level numbers, the Net Profit for Q4 FY26 stood at ₹95.65 crore, a decline of 16.5% YoY. To the untrained eye, this looks like a slowdown. To a seasoned analyst, it’s the cost of a reset.

The company is operating in a high-stakes environment where governance is the primary currency. The “red flags” that once haunted this counter—misappropriation of funds, RBI Corrective Action Plans (CAP), and lender lawsuits—are being systematically burned in the furnace of compliance.

• The Insurance Paradox: Care Health Insurance is growing like a weed, with Gross Written Premiums (GWP) hitting ₹11,417 crore for FY26, up 24%. However, due to the new 1/n accounting rule, a large chunk of this profit is being “deferred,” making the reported PBT look far leaner than the actual cash coming in.
• The Lending Resurrection: Religare Finvest (RFL), which was essentially a “zombie NBFC” for years, has reported a PAT of ₹138.8 crore for FY26. It is now debt-free with a CRAR of 261.9%. This is unheard of in the lending space and suggests RFL is sitting on a mountain of cash, waiting for the demerger to start aggressive lending again.
• The Promoter Puzzle: The Burman family has converted warrants and bought shares from the open market, moving from a “hostile” takeover perception to an “official promoter” designation. This provides the company with the one thing it lacked for a decade: Permanent Capital and Long-term Vision.

The curiosity here lies in the Valuation Gap. While the consolidated entity trades at a P/E of 86, the sum-of-the-parts (SOTP) valuation is the real game. How much is a debt-free NBFC with ₹591 crore in cash worth when paired with India’s 2nd largest standalone health insurer? The market is currently trying to price in the demerger, but the “accounting noise” is keeping the volatility high.

2. Introduction

Religare Enterprises Limited (REL) is a diversified financial services engine that has survived a near-death experience. Founded in 1984, the company was once the poster child for the “Singh Brothers” era, which ended in a spectacular fallout involving misappropriation of over ₹2,500 crore.

Today, it is a Listed Core Investment Company (CIC). It doesn’t do business directly; it owns the titans that do. Its portfolio is divided into four distinct silos:

1. Health Insurance: Care Health Insurance (63.2% stake).
2. Retail Broking: Religare Broking Limited (100% stake).
3. SME Lending: Religare Finvest Limited (100% stake).
4. Housing Finance: Religare Housing Development Finance (87.5% stake).

The current management, under the shadow of the Burman Group, is aggressively trying to distance the company from its past. This involves not just changing the board, but changing the business model from a “conglomerate mess” to a “specialized play.”

The latest quarterly results for March 2026 show a consolidated total income of ₹2,473.30 crore. While the expenses have ballooned to ₹2,346 crore—partly due to one-time employee provisions tied to the new labor code—the operating engine is clearly revving. The company is now a “Battlefield Stock,” where institutional interest is rising as the legacy litigation clouds clear.

3. Business Model – WTF Do They Even Do?

If you think Religare is just another finance company, you’re missing the forest for the trees. REL is essentially a Venture Capital fund for its own subsidiaries. ### The Care Health Insurance Engine (The Cash Cow)

This is the heart of the company. It accounts for nearly 75% of the total revenue. It operates in the Standalone Health Insurance (SAHI) space, which is currently the fastest-growing segment in Indian insurance. They sell peace of mind to 10 lakh+ customers. With a network of 22,000+ hospitals, they are essentially a tech-platform that manages health risk.

The Broking & E-Governance Arm

Religare Broking is the “old guard.” It has survived the discount broking onslaught by pivoting to a hybrid model. They have 2.5 lakh active clients and 68 branches. The “sexy” part of this business is the E-Governance division, which handles PAN cards, Aadhaar, and GST registrations through a massive network of 61,000+ agents. It’s a low-margin but high-stickiness business.

The Lending “Zombie” (RFL & RHDFCL)

This is the part that is being “reborn.” Religare Finvest (RFL) used to be a massive SME lender until it was barred by the RBI in 2018. Now, it’s a Debt-Free shell with ₹591 crore in liquid funds. The business model here is currently “Recovery & Litigate.” They are chasing old money while preparing to relaunch SME loans post-demerger. Religare Housing (RHDFCL) handles ticket sizes of ₹10 lakh in smaller towns—essentially lending to the “un-banked” self-employed class.

Wisdom Check: In finance, a business model is only as good as its cost of capital. Religare’s previous model failed because the promoters used the company as a personal ATM. The new model is built on “Siloed Accountability,” where each subsidiary must stand on its own feet.

4. Financials Overview

The numbers for Q4 FY26 reflect a company in a heavy investment phase. The management has explicitly stated they are building a “strong operating foundation rather than chasing short-term growth optics.”

Key Quarterly Performance (Consolidated)

*Note: Q4 EPS is not annualised as per the full-year reporting rule.

Management “Walk the Talk” Analysis:

In the February 2026 ConCall, the management mentioned that Q3 results were hit by one-time employee benefit provisions. Looking at Q4, the Profit Before Tax (PBT) recovered to ₹127.17 crore (from a loss of ₹103 crore in Q3). They have successfully stabilized the “core operations” as promised, though the EBITDA margins are still under pressure due to the aggressive expansion of the Care Health sales force and digital upgrades in the Broking arm.

5. Valuation Discussion – Fair Value Range

Calculating the fair value for a “Holding Company” like Religare is a nightmare because of the HoldCo Discount. Markets typically penalize holding companies by 30-50%. However, the demerger is designed to kill this discount.

Method 1: P/E Based Valuation (Post-Demerger Proxy)

The Health Insurance sector (SAHI) trades at aggressive multiples. Peers like Star Health trade around 35-40x P/E.

• Annualised Consolidated EPS: Based on FY26 PAT of ₹73.16 Cr and 33.3 Cr shares, the FY26 EPS is ₹2.19.
• At a 40x multiple (Insurance focus), the value is roughly ₹88.
• However, this doesn’t account for the ₹2,575 crore in reserves and the cash-rich RFL.

Method 2: EV/EBITDA

• Enterprise Value (EV): Market Cap (₹7,395 Cr) + Debt (₹493 Cr) – Cash (₹1,703 Cr) = ₹6,185 Cr.
• FY26 EBITDA: ~₹136 Cr.
• EV/EBITDA: ~45.4x. This is high for a traditional NBFC but par for the course for a high-growth insurance play.

Method 3: Sum-of-the-Parts (SOTP)

• Care Health (63% stake): Valued at a conservative 3x GWP (₹11,417 Cr) = ₹34,251 Cr. Religare’s share = ₹21,600 Cr.
• Religare Finvest (Book Value): ~₹900 Cr.
• Broking (10x PAT): ~₹220 Cr.
• Total SOTP Value = ~₹22,720 Cr.
• Applying a 50% HoldCo Discount = ₹11,360 Cr.
• Current Market Cap = ₹7,395 Cr.

Fair Value Range: ₹310 – ₹365 per share.

Disclaimer: This fair value range is for educational purposes only and is not investment advice.

6. What’s Cooking – News, Triggers, Drama

Religare is currently a 24/7 drama series. If you aren’t watching the exchange filings, you’re missing out.

• The Demerger Bomb: On February 14, 2026, the board approved splitting the company. For every 1 share of REL, you get 1 share of RFL. This is the ultimate “Value Unlock” trigger. The goal is to list RFL by Q1 FY28.
• The Burman Takeover: The Burman group converted 19.85 lakh warrants in December 2025. They are now buying from the open market. This is a clear signal: the big boys think the stock is cheap.
• The GST Nightmare: Care Health Insurance received a ₹17.68 crore GST penalty recently. The Bombay High Court stayed it, but it shows the regulatory heat the sector is under.
• Management Shuffle: A new CEO for Religare Finvest (Srinivasan Karthik) and a new MD for Care Health (Ajay Kumar Shah) were appointed in April 2026. New blood usually means new targets.

Are you watching the “Free Float”? With Promoters and Institutions holding nearly 47%, the public float is shrinking. What happens when the demerger actually hits?

7. Balance Sheet

Religare’s balance sheet has transformed from a “toxic waste site” to a fortress of liquidity. The Borrowings have dropped significantly over the last few years as they settled with lenders.

Latest Consolidated Balance Sheet (Mar 2026)

Auditor’s Sarcastic Notes:

• The Borrowings are just ₹493 crore on an asset base of ₹14,506 crore. This company is so under-leveraged it’s almost offensive for a financial services player.
• The “Other Liabilities” at ₹11,104 crore are mostly “Insurance Reserves.” Basically, it’s money they owe to policyholders if they get sick. It’s “good debt” that earns investment income.
• The Net Worth has jumped by ₹400 crore in a year. The “hole” left by the previous promoters is finally being filled with actual earnings and warrant conversions.

8. Cash Flow – Sab Number Game Hai

In financial services, cash flow is king. You can fake profits with accruals, but you can’t fake cash in the bank.

Where did the money go?

The company generated a massive ₹1,820 crore from operations. Where did it go? It went straight into the “Investing” bucket (-₹2,176 Cr). They aren’t buying factories; they are buying Government Securities and Corporate Bonds to back their insurance claims. The Financing cash flow turned positive because of the ₹410 crore received from warrant conversions by the Burman Group.

9. Ratios – Sexy or Stressy?

The ratios show a company that is Safe but Inefficient.

The Verdict:

The ROE of 3.17% is frankly depressing. A fixed deposit gives better returns. However, this is artificially low because the “Net Worth” is bloated with cash that hasn’t been deployed yet. The Debt to Equity of 0.17 is the “Sexy” part—they have immense room to borrow and grow the lending book once the demerger is done.

10. P&L Breakdown – Show Me the Money

Religare’s P&L is essentially a story of two different worlds: The growing insurance premium and the shrinking interest expense.

Stand-up Comedy Commentary:

The revenue is going up, but the net profit is going down. Why? Because the company is spending like a teenager with a new credit card on “Other Expenses” (₹8,324 Cr). They are hiring top-tier talent from Bajaj Finance and UTI MF, upgrading IT systems, and fighting legal battles. They are “buying” their future growth, and for now, the bottom line is paying the price.

11. Peer Comparison

Religare is a weird beast. It’s part JSW Holdings, part Aditya Birla Capital.

Sarcastic Notes:

• Jio Financial is the school topper who hasn’t even written the exam yet but everyone assumes will get 100%.
• Aditya Birla Capital is the hardworking corporate employee with massive revenue but steady growth.
• Religare is the guy who just got out of rehab (RBI CAP) and is trying to prove he can run a marathon. It’s small, scrappy, and its P/E is “crying” because the earnings haven’t caught up to the market’s optimism.

12. Miscellaneous – Shareholding and Promoters

The shareholding pattern is the most important part of the Religare story. It’s where the “Game of Thrones” is being played.

The Promoter Roast:

The Burman family (via Puran Associates and Vic Enterprises) is now the “Official Captain.” They’ve increased their stake by 4% in just one quarter. Meanwhile, the public is selling. Usually, when the smart money (Promoters) buys and the “weak hands” (Public) sell, something big is about to happen.

Anchor Watch: Names like Ashish Dhawan (4.12%) and Plutus Wealth Management are still in the mix. These aren’t just investors; they are sharks who smell blood in the water (in a good way).

13. Corporate Governance – Angels or Devils?

Religare is in the “Angelic Transformation” phase. After the Singh brothers’ “Devil” phase, the new board is obsessed with compliance.

The audit trail is now cleaner than a surgical room. They have reconstituted the boards of all subsidiaries. The induction of Dr. Anand Burman and Mohit Burman as Non-Executive Directors is the final stamp of institutional credibility. However, legacy ghosts remain. The ₹750 crore FD litigation with DBS (formerly LVB) is still sub-judice in the Delhi High Court. They’ve fully provisioned for it, so any recovery will be a “jackpot” for the P&L.

14. Industry Roast and Macro Context

The Indian financial services sector is currently a crowded elevator. Everyone is trying to reach the top floor (Credit & Insurance).

• The Insurance Roast: The regulator (IRDAI) is pushing “Insurance for All by 2047.” This sounds great, but it also means cut-throat competition. The new “1/n” accounting rule is the regulator’s way of saying “Don’t show me paper profits; show me steady growth.”
• The Lending Sector: SME lending is the new “hot girl” in town. Every NBFC from Poonawalla to Jio is chasing SMEs. Religare has a head start with its legacy network, but it’s fighting giants with deeper pockets.
• Macro Sarcasm: With the GST exemption on health insurance premiums, the government has finally realized that taxing someone for being sick is bad optics. This is a massive tailwind for Care Health.

15. EduInvesting Verdict

Religare Enterprises is a “Reconstruction Story.” It is no longer a “Scam Story.”

SWOT Analysis

• Strengths: Debt-free NBFC arm (RFL), 2nd largest health insurer, and strong promoter backing (Burman Group).
• Weaknesses: Low ROE, high operating expenses, and complex holding company structure.
• Opportunities: The demerger value unlock, relaunch of SME lending, and IFRS reporting in Care Health (which will show the “hidden” profits).
• Threats: Regulatory changes in insurance commissions, outcome of the DBS litigation, and intense competition in retail broking.

Past vs. Future:

In the past, Religare was a vehicle for promoter greed. In the future, it aims to be a lean, two-pronged financial machine. The headwinds are mostly “Accounting Deferrals” and “One-time Costs.” The tailwinds are structural: India’s under-penetrated health insurance market and the SME credit gap.

If the management “walks the talk” on the listing of RFL by Q1 FY28, we are looking at a completely different beast. For now, it’s a high-conviction play on management integrity and structural de-risking.

Do you think the market is underestimating the cash-rich RFL shell, or is the Insurance accounting too complex for the average investor to price correctly?